Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
05/2005
05/19/2005US20050107597 Nucleotide sequences coding microorganismal secondary response gene (SPA-1) for as tool in diagnosis, prevention and treatment of pseudomonal infection
05/19/2005US20050107581 Steam stripping beads under vacuum; divinyl benzene/ethyl vinyl benzene copolymers; dilution; for production of cephalosporin C and insulin
05/19/2005US20050107498 coating mixtures having low viscosity, high flexibilities, good strength and low tack, that can be applied to solid products at high spraying rate in high solids concentrations, to form coated product that are smooth, glossy, uniformly colored, disintegrate very rapidly, and are stable on storage
05/19/2005US20050107446 Two components mixture comprising a powder of atorvastatin with an alkalizing agent that forms a pH greater than 5 and a second component without the alkalizing agent; treating angina pectoris, hypertension, atherosclerosis
05/19/2005US20050107438 mixtures of dabigatran etexilate and lipophilic liquid, solid, or semi-solid carriers
05/19/2005US20050107429 Aqueous liquid preparations and light-stabilized aqueous liquid preparations
05/19/2005US20050107344 Bi phosphate containing protonated compound with two end groups; disinfecting surfaces of surgical equipments and skin
05/19/2005US20050107330 Drug mixture contains a sympathomimetic selected from the group consisting oxymetazoline, xylometazoline, tramazoline, tetryzoline and naphazoline, and glycosaminoglycan of hyaluronic acid; synergistic effect; vasoconstrictor action, detumescent action on the nose mucous membrane
05/19/2005US20050107329 Liposome compositions of porphyrin photosensitizers
05/19/2005US20050107302 Applying formulation containing ovalbumin containing a growth factor selected from epidermal growth factor, transforming growth factor alpha, fibroblast growth factors, phenoxyethanol, triethanolamine, carbomer for scar prevention
05/19/2005US20050107294 in an injectable form and to be administered through infiltrations inside and around cutaneous chronic ischemic ulcerative wounds as to prevent diabetic limb amputation
05/19/2005US20050107292 Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
05/19/2005US20050107291 Compositions and methods for treating or preventing diseases of body passageways
05/19/2005US20050107287 Administering cisplatin; drug delivery; reduced dosage to prevent release into systemic circulation; platinum containing compound entrapped in salt crystals; andone or more lipids
05/19/2005US20050107256 Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them
05/19/2005US20050107253 Adsorbent for phosphoric acid
05/19/2005US20050106657 Using fungal propagation and fermentation to generate carotenoids for use as food and pharmaceutical supplements
05/19/2005US20050106553 Rendering material suitable for storage via spraying into hot gas stream an aqueous mixture and carrier, drying mixture to particles , separating partiles from gas stream; storage of materials by incorporating them into water-soluble or water-swellable substance
05/19/2005US20050106276 Pharmaceutical composition made from Chinese traditional medecine and method of producing thereof
05/19/2005US20050106273 comprising wheat bran, wheat, molasses, and corn-derived maltodextrin in at least one biocompatible oral dosage formulation
05/19/2005US20050106272 Co-beadlet of dha and rosemary and methods of use
05/19/2005US20050106271 containing a clove perfume and a peppermint perfume; suppressing peculiar chemical smells
05/19/2005US20050106269 stimulating increased NO production; neuroprotectant; increased cerebral blood flow
05/19/2005US20050106266 docosahexaenoic acid and a calcium compound (carbonate, hydroxide,sulfate)
05/19/2005US20050106264 cystic fibrosis, chronic bronchitis, and ciliary dyskinesia; expand or increase the volume of periciliary liquid layer on airway surfaces thereby increase or facilitate cough clearance, mucociliary clearance, and/or gas-liquid dependent clearance of mucous
05/19/2005US20050106257 Drugs/biodrugs embedded in polymer matrix via precipitation into solvent forming suspension, mixing with surfactant, then solidifying
05/19/2005US20050106256 Comprises ionic initiator (ammonium persulfate) to promote dispersion polymerization forming polyacrylamide; sustained/time-release
05/19/2005US20050106255 Human tissue engineering, tissue replacement; joint replacement
05/19/2005US20050106254 Method for preparing gels
05/19/2005US20050106253 Enteric coating allows for sustained/timed-release; acid resistance; for treatment of benign prostatic hyperplasia
05/19/2005US20050106252 Time-release agents; mechanical/storage stability; tablets
05/19/2005US20050106251 Zero order controlled drug delivery system
05/19/2005US20050106249 Once-a-day, oral, controlled-release, oxycodone dosage forms
05/19/2005US20050106248 Extended release venlafaxine formulation
05/19/2005US20050106247 Such as capsules/beads of cyclobenzaprine hydrochloride
05/19/2005US20050106246 for treating glutamate dehydrogenase deficiency or increase prolyl hydroxylase and lysyl hydroxylase activity or prevent protein glycation characteristic of atheroscloerosis, cataract formation, retinopathy, and aging; longer therapeutic release times
05/19/2005US20050106245 Sustained release preparations and process for producing the same
05/19/2005US20050106244 Tablets, granules formed by compression
05/19/2005US20050106243 Suspending adsorber material selected from celluloses, polyols, sugar derivatives, maltodextrins, cyclodextrins, starches, and/or polydextroses; pressing
05/19/2005US20050106242 Enhanced dissolution and bioavailibilty of beneficial agents with low water solubility; homogenizing; capsules
05/19/2005US20050106241 Undesirable metabolites associated with first pass effect of selegiline, such as amphetamine and methamphetamine; for treatment of Parkinson's disease, Alzheimers's disease; bioavailability
05/19/2005US20050106240 Composition for rapid disintegrating tablet in oral cavity
05/19/2005US20050106239 Stabilized azithromycin compositions
05/19/2005US20050106238 Orodispersible pharmaceutical composition comprising ivabradine
05/19/2005US20050106237 Orodispersible pharmaceutical composition comprising perindopril
05/19/2005US20050106236 5-Ht4partial agonist pharmaceutical compositions
05/19/2005US20050106235 Nsaid formulation comprising a granular composition and an extra-granular composition
05/19/2005US20050106234 Calcium formate for use as a dietary supplement
05/19/2005US20050106233 Seamless; high oil content; formed by emulsion comprising oil, water, emulsifier (polyoxyethylene glycol-sorbitan monolaurate), water-soluble monovalent/polyvalent metal salt (calcium chloride), and acid; marmelo mucilage free; gelation
05/19/2005US20050106231 Liposome-entrapped topoisomerase inhibitors
05/19/2005US20050106230 Drug-enhanced adhesion prevention
05/19/2005US20050106229 Antiscarring agents; using tranilast
05/19/2005US20050106228 Compositions for the treatment and prevention of cancer
05/19/2005US20050106227 Transdermal drug delivery
05/19/2005US20050106226 Pretreatment method and system for enhancing transdermal drug delivery
05/19/2005US20050106225 Fluid medication delivery device
05/19/2005US20050106223 Multilayer personal cleansing and/or moisturizing article
05/19/2005US20050106222 Genetic engineering; gene expression; polypeptides
05/19/2005US20050106221 Kit for the treatment of a corn or a callus
05/19/2005US20050106216 Oral compositions of fenretinide having increased bioavailability and methods of using the same
05/19/2005US20050106214 Excipients in drug delivery vehicles
05/19/2005US20050106211 Fabrication of drug loaded biodegradable polymer fibers
05/19/2005US20050106210 Solvent mixture containing silicone and active mateerials; controlling particle sizes of active materials
05/19/2005US20050106209 Composition and apparatus for transdermal delivery
05/19/2005US20050106206 Application of a therapeutic substance to a tissue location using an expandable medical device
05/19/2005US20050106205 Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
05/19/2005US20050106202 Endoparasiticidal gel composition
05/19/2005US20050106191 Antiseptic bactericides and cosmetics, drugs and foods containing the antiseptic bactericides
05/19/2005US20050106189 Pharmaceutical formulation comprising cyclosporin and use thereof
05/19/2005US20050106186 Percutaneous preparations
05/19/2005US20050106157 Immunogenic formulations comprising oil bodies
05/19/2005US20050106129 Method of obtaining immune cells from an animal
05/19/2005US20050106128 Novel methods of treatment and deliver modes
05/19/2005US20050106127 Graft to humans; culture product; removing cells; preservation
05/19/2005US20050106122 Absorption enhancing agent
05/19/2005US20050106115 Using a dioxaborinane compound
05/19/2005US20050106112 Oral and personal care compositions and methods
05/19/2005US20050106107 TRansdermal drug delivery device; topical applying mycobacterial antigen; diagnosis of tuberculosis
05/19/2005US20050106098 Microparticles and methods for their production
05/19/2005US20050104247 Method for manufacture of films containing insoluble solids embedded in cellulose-based films
05/19/2005DE10348046A1 Production of transdermal or topical matrix, used in skin and wound care, involves reacting polymer matrix containing added liquid fatty ester, paraffin or silicone oil on carrier, extracting additive and applying active agent and adjuvent
05/19/2005DE10347940A1 Selbstemulgierende Zubereitungen A self preparations
05/19/2005DE10024312B4 Verfahren zur Modifizierung der Oberflächen von feinporösen Adsorbentien sowie Verfahren zur Herstellung eines Molekularsiebes unter Anwendung dieses Verfahrens A method for modifying the surface of finely porous adsorbents and processes for preparing a molecular sieve using this method
05/19/2005CA2545158A1 Reagent-containing membranes and laminates and methods of their preparation
05/19/2005CA2545157A1 Disinfecting composition and methods of making and using same
05/19/2005CA2544965A1 Heat moisture treated starch for the treatment of hypoglycaemia
05/19/2005CA2544843A1 Chewable tablet
05/19/2005CA2544745A1 Powder inhaler
05/19/2005CA2544715A1 Dispersions and methods of preparing them
05/19/2005CA2544627A1 Nanoparticulate compositions having a peptide as a surface stabilizer
05/19/2005CA2544344A1 Pharmaceutical formulations of a quinolone antibiotic containing flavouring substances with improved pharmaceutical properties
05/19/2005CA2544258A1 Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same
05/19/2005CA2544257A1 Solid active substance formulation
05/19/2005CA2543940A1 Preparations for topical application and methods of delivering an active agent to a substrate
05/19/2005CA2543639A1 System and method for transdermal vaccine delivery
05/19/2005CA2543610A1 Transdermal analgesic systems having reduced abuse potential
05/19/2005CA2543508A1 Controlled release analgesic suspensions
05/19/2005CA2543485A1 Use of interferon-tau in medicine
05/19/2005CA2543482A1 Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
05/19/2005CA2543280A1 Delivery of polymer conjugates of therapeutic peptides and proteins via coated microporjections
1 ... 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 ... 2991